Research graph
References from Representation of minoritized people with cystic fibrosis in the Cystic Fibrosis Therapeutics Development Network clinical trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2022 · External reference
Cystic fibrosis: a review
10.1001/jama.2023.8120 · 2023 · External reference
Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?
10.1016/j.jcf.2021.03.027 · 2021 · External reference
Clinical trial participants compared with nonparticipants in cystic fibrosis
10.1164/rccm.200502-273oc · 2006 · External reference
Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis
10.1513/annalsats.201603-192bc · 2016 · External reference
Center-level self-study identifies opportunities to advance equity in cystic fibrosis clinical trial participation
10.1016/j.jcf.2023.05.008 · 2023 · External reference
Comparison of the clinical manifestations of cystic fibrosis in black and white patients
10.1016/s0022-3476(98)70441-x · 1998 · External reference
Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California
10.1378/chest.14-2189 · 2016 · External reference
Disparities in mortality of Hispanic patients with cystic fibrosis in the United States. A national and regional cohort study
10.1164/rccm.201711-2357oc · 2018 · External reference
Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population
10.1002/ppul.21037 · 2009 · External reference
Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype
10.1002/ppul.25285 · 2021 · External reference
Left behind: the potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis
10.1016/j.prrv.2021.12.001 · 2022 · External reference
Unresolved reference
2025 · External reference
The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry
10.1513/annalsats.201511-781oc · 2016 · External reference
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation
10.1016/j.jcf.2020.11.008 · 2021 · External reference
Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: results from the prospect study
10.1016/j.jcf.2020.05.010 · 2020 · External reference
Characterizing CFTR modulated sweat chloride response across the CF population: initial results from the CHEC-SC study
10.1016/j.jcf.2022.07.008 · 2023 · External reference
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial
10.1164/rccm.202108-1986oc · 2022 · External reference
Reducing bias through directed acyclic graphs
10.1186/1471-2288-8-70 · 2008 · External reference
Robust causal inference using directed acyclic graphs: the R package ‘dagitty’
10.1093/ije/dyw341 · 2016 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
2006 · External reference
The central role of the propensity score in observational studies for causal effects
10.1093/biomet/70.1.41 · 1983 · External reference
Racial inequity in grant funding from the US National Institutes of Health
10.7554/elife.65697 · 2021 · External reference
The impact of insurance on access to cancer clinical trials at a comprehensive cancer center
10.1158/1078-0432.ccr-10-1451 · 2010 · External reference
Unresolved reference
2006 · External reference
The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis
10.1016/j.jcf.2024.03.013 · 2024 · External reference
Neighborhood socioeconomic status and primary health care: usual points of access and temporal trends in a major US urban area
10.1007/s11524-016-0085-2 · 2016 · External reference
Race, place, and structural racism: a review of health and history in Washington, D.C
10.1377/hlthaff.2021.01805 · 2022 · External reference
Patient-physician racial concordance and the perceived quality and use of health care
10.1001/archinte.159.9.997 · 1999 · External reference
Consent document translation expense hinders inclusive clinical trial enrolment
10.1038/s41586-023-06382-0 · 2023 · External reference
Limited English proficiency and disparities in health care engagement among patients with breast cancer
10.1200/op.20.01093 · 2021 · External reference
Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
10.1136/ijgc-2024-005751 · 2025 · External reference
The CFTR variant profile of Hispanic patients with cystic fibrosis: impact on access to effective screening, diagnosis, and personalized medicine
10.1002/jgc4.1271 · 2020 · External reference
Increasing diversity in clinical trials: overcoming critical barriers
10.1016/j.cpcardiol.2018.11.002 · 2019 · External reference
Patient-centred access to health care: conceptualising access at the interface of health systems and populations
10.1186/1475-9276-12-18 · 2013 · External reference
Unresolved reference
2020 · External reference
Aggregation of Asian-American subgroups masks meaningful differences in health and health risks among Asian ethnicities: an electronic health record based cohort study
10.1186/s12889-019-7683-3 · 2019 · External reference
Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020
10.1016/j.jcf.2023.02.009 · 2023 · External reference
Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals
10.1513/annalsats.201808-564ps · 2019 · External reference
